Table 1.
Patient Characteristics (N = 8)
| Characteristic | Value |
|---|---|
| Age, yr, median (range) | 18.7 (12-28) |
| Sex, male/female, n | 4/4 |
| Diagnosis, n | |
| cALL | 4 |
| Pre-B-ALL | 4 |
| Time from CAR-T19 therapy to vaccination, mo, median (range) | 48 (39-148) |
| Vaccine type: Pfizer-BioNTech, n (%) | 8 (100) |
| Disease state at vaccination: CR, n (%) | 8 (100) |
| Prior HSCT before CAR-T19 therapy, n (%) | 7 (87.5) |
| Patients with complete B cell aplasia, n (%) | 7 (87.5) |
| IgG level, per mg/dL, median (range) | 722 (171-1114) |
| Patients under regular IgG substitution, n (%) | 7 (87.5) |
| Exposure to anti-CD20/22 antibodies 6 mo before vaccination, n (%) | 2 (29) |
| Total lymphocyte count before first vaccination, /µL, median (range) | 977 (350-2240) |
| Prior exposure to SARS-CoV-2, n (%) | 0 (0) |
cALL indicates common acute lymphoblastic leukemia; B-ALL, B cell acute lymphoblastic leukemia.